MacroGenics Announces Date of First Quarter 2025 Financial Results
MacroGenics (NASDAQ: MGNX), a biopharmaceutical company specializing in monoclonal antibody-based cancer therapeutics, has announced it will release its Q1 2025 financial results after market close on Tuesday, May 13, 2025. The company has stated it will not host a conference call to discuss the quarterly results or corporate progress for the period ending March 31, 2025, though it may resume quarterly conference calls in the future.
MacroGenics (NASDAQ: MGNX), un'azienda biofarmaceutica specializzata in terapie oncologiche basate su anticorpi monoclonali, ha annunciato che pubblicherà i suoi risultati finanziari del primo trimestre 2025 dopo la chiusura del mercato di martedì 13 maggio 2025. La società ha dichiarato che non terrà una conference call per discutere i risultati trimestrali o i progressi aziendali relativi al periodo conclusosi il 31 marzo 2025, anche se potrebbe riprendere le conference call trimestrali in futuro.
MacroGenics (NASDAQ: MGNX), una compañía biofarmacéutica especializada en terapias contra el cáncer basadas en anticuerpos monoclonales, ha anunciado que publicará sus resultados financieros del primer trimestre de 2025 después del cierre del mercado el martes 13 de mayo de 2025. La empresa ha indicado que no realizará una llamada de conferencia para discutir los resultados trimestrales ni los avances corporativos del período que finaliza el 31 de marzo de 2025, aunque podría reanudar las llamadas trimestrales en el futuro.
MacroGenics (NASDAQ: MGNX)는 단클론 항체 기반 암 치료제를 전문으로 하는 생명공학 회사로, 2025년 1분기 재무 실적을 2025년 5월 13일 화요일 시장 마감 후에 발표할 예정이라고 밝혔습니다. 회사는 2025년 3월 31일로 종료되는 분기 실적 및 기업 진행 상황에 대해 논의하는 컨퍼런스 콜을 진행하지 않을 예정이며, 다만 향후 분기별 컨퍼런스 콜을 재개할 수 있다고 전했습니다.
MacroGenics (NASDAQ : MGNX), une société biopharmaceutique spécialisée dans les thérapies anticancéreuses à base d’anticorps monoclonaux, a annoncé qu’elle publierait ses résultats financiers du premier trimestre 2025 après la clôture du marché le mardi 13 mai 2025. La société a précisé qu’elle ne tiendrait pas de conférence téléphonique pour discuter des résultats trimestriels ou des progrès de l’entreprise pour la période se terminant le 31 mars 2025, bien qu’elle puisse reprendre ces conférences trimestrielles à l’avenir.
MacroGenics (NASDAQ: MGNX), ein biopharmazeutisches Unternehmen, das sich auf monoklonale Antikörper-basierte Krebstherapeutika spezialisiert hat, hat angekündigt, seine Finanzergebnisse für das erste Quartal 2025 nach Börsenschluss am Dienstag, den 13. Mai 2025, zu veröffentlichen. Das Unternehmen gab bekannt, dass es keine Telefonkonferenz zur Besprechung der Quartalsergebnisse oder des Unternehmensfortschritts für den Zeitraum bis zum 31. März 2025 abhalten wird, jedoch künftig möglicherweise wieder vierteljährliche Telefonkonferenzen durchführt.
- None.
- None.
ROCKVILLE, MD, May 06, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the first quarter of 2025 after the market closes on Tuesday, May 13, 2025.
The Company will not be hosting a conference call to discuss its financial results or corporate progress for the quarter ended March 31, 2025. The Company may resume its practice of hosting quarterly results conference calls in the future.
About MacroGenics, Inc.
MacroGenics (the Company) is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. For more information, please see the Company's website at www.macrogenics.com. MacroGenics and the MacroGenics logo are trademarks or registered trademarks of MacroGenics, Inc.
Contacts: Jim Karrels, Senior Vice President, CFO 1-301-251-5172 info@macrogenics.com Argot Partners 1-212-600-1902 macrogenics@argotpartners.com
FAQ
When will MacroGenics (MGNX) release its Q1 2025 earnings?
Will MacroGenics (MGNX) host a Q1 2025 earnings call?
What is MacroGenics' (MGNX) main business focus?
Will MacroGenics (MGNX) resume quarterly earnings calls in the future?
